ICU Medical (ICUI) officer sells 2,897 shares at $152.35

ICU Medical, Inc. (ICUI) insider transaction: company officer Daniel Woolson, listed as VP, GM-Infusion Capital, reported selling 2,897 shares of ICUI common stock in an open market transaction on 11/25/2025, at a price of $152.3522 per share.

Rhea-AI Filing Summary

ICU Medical, Inc. (ICUI) insider transaction: company officer Daniel Woolson, listed as VP, GM-Infusion Capital, reported selling 2,897 shares of ICUI common stock in an open market transaction on 11/25/2025, at a price of $152.3522 per share. After this sale, he beneficially owns 11,297 shares of ICU Medical common stock.

Insider Trade Summary

Net Seller: 2,897 shares

Net Sell 1 txn

Insider Woolson Daniel

Role VP, GM-Infusion Capital

Sold 2,897 shs ($441K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,897	$152.3522	$441K

Holdings After Transaction: Common Stock — 11,297 shares (Direct)

Footnotes (1)

1. F1. All shares sold were sold at the exact price disclosed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ICU Medical (ICUI) report for Daniel Woolson?

ICU Medical reported that officer Daniel Woolson, VP, GM-Infusion Capital, sold 2,897 shares of ICUI common stock on 11/25/2025.

At what price were the ICUI shares sold by Daniel Woolson?

The reported sale price was $152.3522 per ICUI share, and the explanation notes that all shares were sold at this exact price.

How many ICU Medical (ICUI) shares does Daniel Woolson own after the sale?

Following the reported transaction, Daniel Woolson beneficially owns 11,297 shares of ICU Medical common stock.

What type of filing reported the ICU Medical (ICUI) insider sale?

The transaction was reported on a Form 4, which discloses changes in the beneficial ownership of a company’s securities by its officers, directors, and certain shareholders.

What is Daniel Woolson’s relationship to ICU Medical (ICUI)?

He is identified as an officer of ICU Medical with the title VP, GM-Infusion Capital, and not as a director or 10% owner.

Did the Form 4 indicate that all ICUI shares were sold at the same price?

Yes. The explanation of responses states that all shares sold were sold at the exact price disclosed, which is $152.3522 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 03:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Woolson Daniel

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CA 92673

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, GM-Infusion Capital

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		S		2,897	D	$152.3522(1)	11,297	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All shares sold were sold at the exact price disclosed.

	By: Paula Darbyshire, Attorney-in-Fact For: Daniel Woolson	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.